Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-06-18

LAntibiotic Production: Technology, Optimization and improved Process

Ziel

The focus of this proposal is to develop an economically viable production process for the lantibiotic NAI-107, a new antibiotic with the potential to treat life-threatening infections caused by multidrug-resistant Gram-positive pathogens. NAI-107 is produced by fermentation of the actinomycete Microbispora sp., is undergoing formal toxicology studies and is expected to enter Phase I clinical trials in the second half of 2009. NAICONS, an SME participating in the project and acting as coordinator, is developing NAI-107. A challenge in advancing a new antibiotic into clinical development is to devise a production process that will deliver a high quality compound at reasonable yields. This is particularly relevant for NAI-107 since no lantibiotics are industrially produced as drugs for human use and there are no examples of industrial use of Microbispora. The development of a robust and economically feasible production process for NAI-107 requires the integration of basic knowledge of the physiology of the strain which can be best obtained by a combination of classical and post-genomic approaches (proteome/transcriptome), with a detailed knowledge of the production process and its scalability to industrial level. This will be achieved by flux analyses and 2D-maps for discovering primary metabolism proteins up-regulated during antibiotic production. Combined with a study of other limiting steps, such as precursor uptake, product excretion and the intrinsic resistance of the producing strain, and with analysis of the transcriptional regulation of the NAI-107 biosynthetic genes, bottlenecks in production will be identified and bypassed by metabolic engineering leading to an optimized metabolic pathway for the production of this life-saving antibiotic and an efficient production process utilizing a high producing strain, an improved production medium and an efficient recovery process.

Wissenschaftliches Gebiet

CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.

Aufforderung zur Vorschlagseinreichung

FP7-KBBE-2009-3
Andere Projekte für diesen Aufruf anzeigen

Koordinator

New Anti-infective Consortium
EU-Beitrag
€ 553 400,00
Adresse
Via Fantoli 16/15
20138 Milano
Italien

Auf der Karte ansehen

Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Margherita Sosio (Dr.)
Links
Gesamtkosten
Keine Daten

Beteiligte (6)